Monte Financial Group LLC Has $715,000 Position in Pfizer Inc. (PFE)
Monte Financial Group LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.9% during the 4th quarter, Holdings Channel reports. The institutional investor owned 16,380 shares of the biopharmaceutical company’s stock after buying an additional 298 shares during the period. Monte Financial Group LLC’s holdings in Pfizer were worth $715,000 as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in PFE. Vanguard Group Inc. raised its stake in shares of Pfizer by 1.5% in the third quarter. Vanguard Group Inc. now owns 441,792,969 shares of the biopharmaceutical company’s stock valued at $19,469,816,000 after buying an additional 6,620,749 shares during the period. Vanguard Group Inc raised its stake in shares of Pfizer by 1.5% during the 3rd quarter. Vanguard Group Inc now owns 441,792,969 shares of the biopharmaceutical company’s stock valued at $19,469,816,000 after purchasing an additional 6,620,749 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Pfizer by 3.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 70,231,649 shares of the biopharmaceutical company’s stock valued at $3,095,110,000 after purchasing an additional 2,497,736 shares during the period. Morgan Stanley raised its stake in shares of Pfizer by 2.1% during the 3rd quarter. Morgan Stanley now owns 55,493,846 shares of the biopharmaceutical company’s stock valued at $2,445,614,000 after purchasing an additional 1,126,612 shares during the period. Finally, Fisher Asset Management LLC raised its stake in shares of Pfizer by 3.3% during the 4th quarter. Fisher Asset Management LLC now owns 41,830,709 shares of the biopharmaceutical company’s stock valued at $1,825,910,000 after purchasing an additional 1,352,978 shares during the period. 69.17% of the stock is currently owned by institutional investors.
In other news, major shareholder Pfizer Inc acquired 50,000 shares of the business’s stock in a transaction dated Monday, May 13th. The stock was purchased at an average cost of $17.00 per share, for a total transaction of $850,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Mikael Dolsten sold 149,553 shares of the company’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $43.55, for a total value of $6,513,033.15. Following the completion of the transaction, the insider now owns 390,097 shares of the company’s stock, valued at $16,988,724.35. The disclosure for this sale can be found here. Insiders sold a total of 288,726 shares of company stock worth $12,534,617 over the last 90 days. Corporate insiders own 0.09% of the company’s stock.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, April 30th. The biopharmaceutical company reported $0.85 earnings per share for the quarter, topping analysts’ consensus estimates of $0.75 by $0.10. The business had revenue of $13.12 billion for the quarter, compared to analyst estimates of $13.01 billion. Pfizer had a return on equity of 27.48% and a net margin of 21.31%. The company’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.77 EPS. Research analysts forecast that Pfizer Inc. will post 2.89 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 10th will be paid a $0.36 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.44 dividend on an annualized basis and a yield of 3.50%. Pfizer’s dividend payout ratio is currently 48.00%.
A number of research firms recently issued reports on PFE. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $55.00 price objective on the stock in a research note on Thursday, January 31st. Zacks Investment Research lowered Pfizer from a “hold” rating to a “sell” rating in a research note on Friday, January 25th. Credit Suisse Group reiterated a “buy” rating and set a $48.00 price objective on shares of Pfizer in a research note on Monday, May 6th. Barclays reiterated a “hold” rating and set a $41.00 price objective on shares of Pfizer in a research note on Thursday, May 9th. Finally, Bank of America boosted their price objective on Pfizer from $45.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, April 1st. Fourteen research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $45.83.
TRADEMARK VIOLATION WARNING: This news story was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2019/05/16/monte-financial-group-llc-has-715000-position-in-pfizer-inc-pfe.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Further Reading: How are dividend achievers different from dividend aristocrats?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.